Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-03-26 @ 3:17 PM
NCT ID:
NCT07308951
Eligibility Criteria:
Inclusion Criteria:
* Age between 18 and 80 years, regardless of gender;
* Diagnosis of primary or metastatic malignant tumor confirmed by histopathology and/or cytology, consistent with the American Cancer Society criteria for malignancy;
* Presence of cancer-related pain, defined as an average Numeric Rating Scale (NRS) score ≥ 2 over the preceding week or current regular use of opioid analgesics;
* Life expectancy ≥ 3 months;
* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score ≤ 2, stable vital signs, clear consciousness, intact pain perception, unimpaired communication, ability to cooperate with study procedures and complete assessments;
* Provision of signed informed consent by the patient or their legal guardian after comprehensive explanation of the study;
Exclusion Criteria:
* Pain not attributable to cancer;
* Severe cardiopulmonary dysfunction or respiratory depression;
* Implantation of cardiac pacemaker or metallic implants at stimulation sites;
* Local skin lesions or conditions unsuitable for TEAS at the acupoint sites;
* Severe psychiatric disorders or significant cognitive impairment;
* Concurrent participation in other clinical trials that may interfere with the outcome evaluation of this study;
* Previous history of transcutaneous electrical acupoint stimulation (TEAS) or transcutaneous electrical nerve stimulation (TENS);
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT07308951
Study Brief:
Protocol Section:
NCT07308951